Equities research analysts expect Five Prime Therapeutics Inc (NASDAQ:FPRX) to post ($1.29) earnings per share for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Five Prime Therapeutics’ earnings, with the highest EPS estimate coming in at ($1.04) and the lowest estimate coming in at ($1.51). Five Prime Therapeutics reported earnings of ($0.73) per share in the same quarter last year, which suggests a negative year-over-year growth rate of 76.7%. The firm is scheduled to report its next quarterly earnings report on Thursday, February 22nd.

According to Zacks, analysts expect that Five Prime Therapeutics will report full year earnings of ($5.56) per share for the current financial year, with EPS estimates ranging from ($5.84) to ($5.38). For the next financial year, analysts anticipate that the firm will report earnings of ($5.00) per share, with EPS estimates ranging from ($6.65) to ($3.23). Zacks’ EPS averages are an average based on a survey of research analysts that cover Five Prime Therapeutics.

Five Prime Therapeutics (NASDAQ:FPRX) last announced its earnings results on Monday, November 6th. The biotechnology company reported ($1.54) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.35) by ($0.19). Five Prime Therapeutics had a negative return on equity of 41.57% and a negative net margin of 408.42%. The business had revenue of $8.33 million for the quarter, compared to analysts’ expectations of $16.16 million. During the same period in the previous year, the firm posted ($0.72) earnings per share. The firm’s revenue was up 24.7% compared to the same quarter last year.

A number of brokerages have recently issued reports on FPRX. ValuEngine lowered Five Prime Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, November 7th. BMO Capital Markets lifted their target price on Five Prime Therapeutics from $71.00 to $75.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 7th. Zacks Investment Research lowered Five Prime Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, November 9th. BidaskClub raised Five Prime Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, December 21st. Finally, Royal Bank of Canada reaffirmed a “buy” rating and set a $41.00 target price on shares of Five Prime Therapeutics in a research report on Wednesday, October 25th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $64.00.

In related news, Director William R. Ringo sold 600 shares of the business’s stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $45.33, for a total value of $27,198.00. Following the completion of the sale, the director now directly owns 600 shares of the company’s stock, valued at $27,198. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 6.50% of the stock is owned by insiders.

A number of institutional investors have recently made changes to their positions in the stock. Legal & General Group Plc increased its holdings in Five Prime Therapeutics by 3.1% in the second quarter. Legal & General Group Plc now owns 9,455 shares of the biotechnology company’s stock valued at $288,000 after buying an additional 287 shares during the last quarter. The Manufacturers Life Insurance Company increased its holdings in Five Prime Therapeutics by 1.9% in the second quarter. The Manufacturers Life Insurance Company now owns 21,449 shares of the biotechnology company’s stock valued at $646,000 after buying an additional 397 shares during the last quarter. Rhumbline Advisers boosted its stake in Five Prime Therapeutics by 1.4% in the second quarter. Rhumbline Advisers now owns 34,282 shares of the biotechnology company’s stock valued at $1,032,000 after acquiring an additional 484 shares during the period. Cornerstone Capital Management Holdings LLC. boosted its stake in Five Prime Therapeutics by 3.0% in the second quarter. Cornerstone Capital Management Holdings LLC. now owns 17,227 shares of the biotechnology company’s stock valued at $518,000 after acquiring an additional 494 shares during the period. Finally, Voya Investment Management LLC boosted its stake in Five Prime Therapeutics by 9.5% in the second quarter. Voya Investment Management LLC now owns 12,594 shares of the biotechnology company’s stock valued at $379,000 after acquiring an additional 1,097 shares during the period. 83.66% of the stock is owned by hedge funds and other institutional investors.

Shares of Five Prime Therapeutics (NASDAQ:FPRX) opened at $20.54 on Wednesday. Five Prime Therapeutics has a 52-week low of $19.73 and a 52-week high of $49.30. The stock has a market capitalization of $613.03, a PE ratio of -4.06 and a beta of 3.91.

ILLEGAL ACTIVITY NOTICE: “Zacks: Brokerages Anticipate Five Prime Therapeutics Inc (FPRX) to Announce -$1.29 Earnings Per Share” was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright laws. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/01/17/zacks-brokerages-anticipate-five-prime-therapeutics-inc-fprx-to-announce-1-29-earnings-per-share.html.

Five Prime Therapeutics Company Profile

Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.

Get a free copy of the Zacks research report on Five Prime Therapeutics (FPRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.